CATX - Rasio utang marang kapitalisasi buku Perspective Tx

Perspective Therapeutics (CATX) is developing innovative tumor-fighting methods through radiopharmaceuticals. The company's market price action reflects a current metric of 0.01, while the business relies on the critical importance of oncology, which minimizes the impact of external crises. The firm is investing in the targeted implementation of isotopes to achieve medical leadership. Preclinical efficiency is increasing through the deployment of automated drug screening systems.

This indicator measures the proportion of borrowed funds relative to the total book value of equity, determining the level of financial leverage and the company's dependence on external borrowing. By analyzing debt obligations against the balance sheet capital structure, an investor assesses the stability of Perspective Therapeutics (CATX), which is supported by its operations in the protected radiopharmaceutical sector, a field virtually immune to geopolitical shocks and trade restrictions.